Because of the limited treatment options available for advanced TFE3‐RCC, standard therapies developed for KIRC have been used, but with varying outcomes.[2, 15, 16, 17, 18] Alternative drugs, such as cabozantinib (a MET inhibitor),[19, 20] may be effective for some but not all TFE3‐RCC patients, as MET expression levels vary. The gene discussed is MET; the disease is renal cell carcinoma.